Officially unveiled at the American Society of Human Genetics (ASHG) 2025 meeting held in Boston, Genomics has launched Mystra, an AI-enabled human genetics platform designed to accelerate drug target ...
Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...
Zacks Investment Research on MSN
OCGN gene-agnostic eye therapy could shift retinal drug development
Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single ...
Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward ...
Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.
GUEST COMMENTARY—For millions of patients, the slow pace of drug discovery means years – sometimes decades – without effective treatments. Many diseases remain untreatable, not because they are rare ...
Cells face constant threats from inside and out. Thus, they’ve evolved sophisticated stress response pathways such as the unfolded protein response (UPR), ...
London biotech startup Ternary Therapeutics has raised £3.6m to scale its AI-powered platform designed to engineer molecular ...
Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results